Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Pain, Pleasure and Postrel | Main | Forecasting Happiness »

September 9, 2003

Neurotechnology Leaders Forum in San Francisco Today

Email This Entry

Posted by Zack Lynch

Congratulations to James Cavuoto and Neurotech Reports team for putting together a stimulating day conference on the neuro-electronic technology industry.

Neurotechnology Industry - Electronic Sector

Neurotech Reports defines neurotechnology as the application of electronics and engineering to the nervous system.

This is different than the broader definition of neurotechnology used by the Economist, Susan Greenfield and here on Brain Waves.


Neuroelectronic market segments

Critical industry issues: Educating clinicians, reimbursement by insurance, regulatory hurdles and implantation bias

Leading neuroelectronic companies: Medtronic, ANS, Cyberonics, Advanced Bionics, Neuropace



  1. Neural prostheses -- Size of cochlear implant market is $500M in 2003 - $1.6B in 2008), (retinal implants viable market by 2007, 2008)


  2. Neuromodulation -- Use of electronic stimulation to induce and restore desired function (e.g. urinary urge incontinence for spinal chord injury patients) Neural modulation market estimate is $800m in 2004 - $3B in 2008. Deep brain stimulation also growing for Parkinson’s.

  3. Therapeutic stimulation – Stimulators to reduce pain (e.g. Advanced Bionics—Bion)

  4. Neurodiagnostics – Equipment used to read electrical nervous systems

  5. Neural-computer interfaces – Use of nervous system signals to drive external

Addicted to Neurotechnology: A User’s perspective

What do a substance abuser and neurotechnology user have in common?

According to Jennifer French, a periplegic who uses a neural stimulation system that has allowed her to stand (with a walker) at her wedding and balance on boats, there are a few interesting similarities: both are addicts, both require time to develop that addiction and both are life changing. Her joke excluded, Jennifer is the executive director of the Society To Increase Mobility (STIM) a non-profit that disseminates information about neurotechnology to users.

For Jennifer, neurotechnology is not a market, not a product, but a whole new way to increase people’s quality of life. “It is life changing.”


New Neural Stimulation NSF Engineering Research Center Announced

A collaboration among USC, UC Santa Cruz and Caltech in cooperation with AMI has secured $20M in funding over five years.


Wireless Disposable Brain Imaging

10% of the population suffers from sleep apnea, but only 10% even know it.

Advanced Brain Monitoring has produced a new disposable brain EEG system (where the electrodes are disposable not the EEG--thanks Chris) that monitors alertness and drowsiness. ABM has received $7M in funding from NIH and DARPA. Their ARES system is inexpensive, non-invasive, 6 channel, bi-directional radio frequency transmission, can be comfortably worn for 8 hours, and is powered by 2 AA batteries.

Check out ABM’s tag line: Brain monitoring in the home, at work and on demand.

Neurotechnology VC's

The venture capital discussion focused on the differences between medical device and biopharmaceutical company valuations and exit strategies. Last IPO window for medical device companies was 1996 and most of the those companies have not done well. Last IPO window for biotech was 2000. Valuations have held up better.


Comments (0) | Category: Neurotech Industry



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20
Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
McGovern Institue for Brain Research at MIT Goes Web 2.0
The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
Neuropharma FDA Approvals Down in 2009
Tel Aviv Neurotech Cluster Thrives